Inhibition of CRM1-mediated nucleocytoplasmic transport: Triggering human melanoma cell apoptosis by perturbing multiple cellular pathways

Journal of Investigative Dermatology

Volumn 132, Issue 12, 2012, Pages 2780-2790

  Pathria, Gaurav ^a   Wagner, Christine ^a   Wagner, Stephan N ^a,b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EXPORTIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; P90 RIBOSOMAL S6 KINASE1; PROTEIN; PROTEIN P21; PROTEIN P53; RAN PROTEIN; RANBP1 PROTEIN; RANGAP1 PROTEIN; S6 KINASE; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA MICROARRAY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; MELANOCYTE; MELANOMA CELL; METASTASIS; NUCLEOCYTOPLASMIC TRANSPORT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84870570626     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.233     Document Type: Article

References (53)

1. Adachi M, Fukuda M, Nishida E (2000) Nuclear export of MAP kinase (ERK) involves a MAP kinase kinase (MEK)-dependent active transport mechanism. J Cell Biol 148:849-56
2. Ajenjo N, Canon E, Sanchez-Perez I et al. (2004) Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells. J Biol Chem 279:32813-23 (Pubitemid 39014741)
3. Aksamitiene E, Kholodenko BN, Kolch W et al. (2010) PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal 22:1369-78
4. Arbiser JL, Fisher DE (2011) Fisetin: a natural fist against melanoma(quest). J Invest Dermatol 131:1187-9
5. Bollag G, Hirth P, Tsai J et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-9
6. Cagnol S, Chambard JC (2010) ERK and cell death: mechanisms of ERKinduced cell death-apoptosis, autophagy and senescence. FEBS J 277:2-21
7. Chan KS, Wong CH, Huang YF et al. (2010) Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 1:e57
8. Clark EA, Golub TR, Lander ES et al. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-5 (Pubitemid 30625739)
9. Drew L, Fine RL, Do TN et al. (2002) The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res 8:3922-32 (Pubitemid 35424787)
10. Flaherty KT, Puzanov I, Kim KB et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 363:809-19
11. Freedman DA, Levine AJ (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 18:7288-93 (Pubitemid 28533048)
12. Fukuda M, Gotoh I, Gotoh Y et al. (1996) Cytoplasmic localization of mitogen-activated protein kinase kinase directed by its NH2-terminal, leucine-rich short amino acid sequence, which acts as a nuclear export signal. J Biol Chem 271:20024-8 (Pubitemid 26281751)
13. Garraway LA, Widlund HR, Rubin MA et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436:117-22 (Pubitemid 40966196)
14. Grossman D, Kim PJ, Schechner JS et al. (2001) Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 98:635-40 (Pubitemid 32105095)
15. Grossman D, McNiff JM, Li F et al. (1999) Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 113:1076-81 (Pubitemid 30013356)
16. Hauge C, Frodin M (2006) RSK and MSK in MAP kinase signalling. J Cell Sci 119:3021-3 (Pubitemid 44322115)
17. Henderson BR, Eleftheriou A (2000) A comparison of the activity, sequence specificity, and CRM1-dependence of different nuclear export signals. Exp Cell Res 256:213-24 (Pubitemid 30211183)
18. Hendrickson AW, Meng XW, Kaufmann SH (2008) Anticancer therapy: boosting the bang of Bim. J Clin Invest 118:3582-4
19. Houben R, Vetter-Kauczok CS, Ortmann S et al. (2008) Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. J Invest Dermatol 128:2003-12 (Pubitemid 352001214)
20. Huang WY, Yue L, Qiu WS et al. (2009) Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 32:E315
21. Jalili A, Moser A, Pashenkov M et al. (2011) Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol 131:1886-95
22. Jiao W, Lin HM, Datta J et al. (2008) Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 27:3156-64 (Pubitemid 351693165)
23. Kau TR, Way JC, Silver PA (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106-17 (Pubitemid 38198739)
24. Knauer SK, Kramer OH, Knosel T et al. (2007) Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 21:207-16 (Pubitemid 46052558)
25. Kuersten S, Ohno M, Mattaj IW (2001) Nucleocytoplasmic transport: ran, beta and beyond. Trends Cell Biol 11:497-503 (Pubitemid 33079143)
26. la Cour T, Gupta R, Rapacki K et al. (2003) NESbase version 1. 0: a database of nuclear export signals. Nucleic Acids Res 31:393-6 (Pubitemid 36150410)
27. Lecane PS, Kiviharju TM, Sellers RG et al. (2003) Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line. Prostate 54:258-67 (Pubitemid 36228162)
28. Leppa S, Saffrich R, Ansorge W et al. (1998) Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J 17:4404-13 (Pubitemid 28362630)
29. Li H, Wang X, Li N et al. (2007) hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem 282:4943-50 (Pubitemid 47100993)
30. Lopez-Bergami P, Huang C, Goydos JS et al. (2007) Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11:447-60 (Pubitemid 46670078)
31. Marais R, Wynne J, Treisman R (1993) The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73:381-93 (Pubitemid 23123315)
32. Marine JC, Lozano G (2010) Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 17:93-102
33. Mutka SC, Yang WQ, Dong SD et al. (2009) Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 69:510-7
34. Nazarian R, Shi H, Wang Q et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7
35. Noske A, Weichert W, Niesporek S et al. (2008) Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer. Cancer 112:1733-43 (Pubitemid 351536833)
36. Rodriguez JA, Span SW, Ferreira CG et al. (2002) CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 275:44-53
37. Rosseland CM, Wierod L, Oksvold MP et al. (2005) Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes. Hepatology 42:200-7 (Pubitemid 40911328)
38. Sakakibara K, Saito N, Sato T et al. (2011) CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118:3922-31
39. Shen A, Wang Y, Zhao Y et al. (2009) Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis. Neurosurgery 65:153-9
40. Smart P, Lane EB, Lane DP et al. (1999) Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B. Oncogene 18:7378-86 (Pubitemid 30032119)
41. Steggerda SM, Paschal BM (2000) The mammalian Mog1 protein is a guanine nucleotide release factor for Ran. J Biol Chem 275:23175-80 (Pubitemid 30646212)
42. Stommel JM, Marchenko ND, Jimenez GS et al. (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18:1660-72 (Pubitemid 29127078)
43. Torii S, Kusakabe M, Yamamoto T et al. (2004) Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell 7:33-44 (Pubitemid 39172686)
44. Tsuchiya A, Tashiro E, Yoshida M et al. (2006) Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression. Oncogene 26:1522-32 (Pubitemid 46398746)
45. Turner JG, Sullivan DM (2008) CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 15:2648-55
46. van der Watt PJ, Maske CP, Hendricks DT et al. (2009) The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 124:1829-40
47. Villanueva J, Vultur A, Lee JT et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-95
48. Vucic D, Stennicke HR, Pisabarro MT et al. (2000) ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10:1359-66
49. Wen W, Meinkoth JL, Tsien RY et al. (1995) Identification of a signal for rapid export of proteins from the nucleus. Cell 82:463-73
50. Wolff B, Sanglier JJ, Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4:139-47 (Pubitemid 27161752)
51. Xu L, Shen SS, Hoshida Y et al. (2008) Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 6:760-9
52. Yang G, Rajadurai A, Tsao H (2005) Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Investig Dermatol 125:1242-51
53. Yoon S, Seger R (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24:21-44 (Pubitemid 43108774).